Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives $15.33 Average Price Target from Brokerages

Aardvark Therapeutics, Inc. (NASDAQ:AARD) has received an average recommendation of “Hold” from the twelve research firms that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $15.3333.

A number of equities analysts recently commented on the stock. Morgan Stanley reiterated an “underweight” rating and issued a $3.00 target price (down from $7.00) on shares of Aardvark Therapeutics in a research report on Friday, May 15th. Wall Street Zen raised Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. HC Wainwright restated a “neutral” rating and issued a $6.00 target price on shares of Aardvark Therapeutics in a report on Monday, July 20th. BTIG Research downgraded shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Weiss Ratings raised shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 2nd.

Aardvark Therapeutics Stock Down 6.1%

Shares of AARD stock opened at $5.38 on Friday. The business has a 50-day moving average price of $6.33 and a two-hundred day moving average price of $5.79. Aardvark Therapeutics has a 12-month low of $3.35 and a 12-month high of $17.94. The firm has a market cap of $117.71 million, a P/E ratio of -1.68 and a beta of 3.74.

Aardvark Therapeutics (NASDAQ:AARD) last released its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.21. As a group, research analysts expect that Aardvark Therapeutics will post -3.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Aardvark Therapeutics in the 2nd quarter worth approximately $42,000. Persistent Asset Partners Ltd purchased a new position in shares of Aardvark Therapeutics during the fourth quarter valued at approximately $56,000. New York State Common Retirement Fund purchased a new position in shares of Aardvark Therapeutics during the second quarter valued at approximately $99,000. MetLife Investment Management LLC bought a new position in shares of Aardvark Therapeutics during the fourth quarter valued at approximately $102,000. Finally, Bank of America Corp DE raised its holdings in shares of Aardvark Therapeutics by 72.9% during the second quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock valued at $108,000 after acquiring an additional 3,369 shares in the last quarter.

Key Aardvark Therapeutics News

Here are the key news stories impacting Aardvark Therapeutics this week:

• Negative Sentiment: The lawsuits allege that Aardvark and certain executives and directors violated federal securities laws by making misleading statements or failing to disclose material information. One investor notice cites former COO Bryan Jones’s description of ARD-101 as having a “very, very clean” safety profile before alleged cardiac observations reportedly led to a Phase 3 pause and a full FDA clinical hold. The allegations have not been proven in court. AARD Shareholder Alert
• Negative Sentiment: Several firms—including Rosen, Hagens Berman, Faruqi & Faruqi, Pomerantz, Schall Brown & Schwartz, and Bronstein Gewirtz & Grossman—are soliciting investors or announcing participation in the pending litigation. The unusually large number of notices increases visibility around Aardvark’s legal and disclosure risks and could add reputational and potential financial liabilities. Rosen Aardvark Investor Notice
• Negative Sentiment: Investors have until October 13, 2026 to seek appointment as lead plaintiff. While this deadline is procedural and does not establish liability, the ongoing case keeps attention focused on potential shareholder losses and the company’s clinical-development disclosures. Hagens Berman Aardvark Class Action Notice

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.